



## PRESS RELEASE

### **Crucell Announces PER.C6<sup>®</sup> Licensing Agreement with Wyeth Pharmaceuticals**

**Leiden, The Netherlands, August 25, 2004** - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a PER.C6<sup>®</sup> research license agreement with Wyeth Pharmaceuticals. This license agreement allows Wyeth to use the PER.C6<sup>®</sup> cell line for its preclinical adenoviral vector-based research and development programs.

Under the terms of the agreement, Crucell will receive an upfront payment and annual maintenance fees. Further financial details were not disclosed.

#### **About Crucell**

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6<sup>®</sup> technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6<sup>®</sup> technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit [www.crucell.com](http://www.crucell.com).

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on February 27, 2004, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

#### **For further information please contact:**

##### **Crucell N.V.**

Elizabeth Goodwin

Director Investor Relations and Corporate  
Communications

Tel. +31 (0)71 524 8718

[e.goodwin@crucell.com](mailto:e.goodwin@crucell.com)